Patents by Inventor Camille Gignoux

Camille Gignoux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
    Patent number: 10183939
    Abstract: This invention relates to novel compounds. The compounds of the invention are kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Raf kinases, e.g., B-Raf and C-Raf. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Raf kinases, for example, cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: January 22, 2019
    Assignee: Redx Pharma PLC
    Inventors: Matilda Bingham, Richard Testar, Camille Gignoux
  • FUSED BICYCLIC (HETERO)AROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS
    Publication number: 20170298061
    Abstract: This invention relates to novel compounds. The compounds of the invention are kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Raf kinases, e.g., B-Raf and C-Raf. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Raf kinases, for example, cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia.
    Type: Application
    Filed: September 11, 2015
    Publication date: October 19, 2017
    Inventors: Matilda Bingham, Richard Testar, Camille Gignoux
  • Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
    Patent number: RE49361
    Abstract: This invention relates to novel compounds. The compounds of the invention are kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Raf kinases, e.g., B-Raf and C-Raf. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Raf kinases, for example, cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: January 10, 2023
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventors: Matilda Bingham, Richard Testar, Camille Gignoux